In-vitro relationship between protein-binding and free drug concentrations of a water-soluble selective beta-adrenoreceptor antagonist (atenolol) and its interaction with arsenic

Journal of Health, Population and Nutrition

Volumn 27, Issue 1, 2009, Pages 20-30

  Alam, M A ^a   Awal, M A ^b   Subhan, N ^c   Mostofa, M ^b  

^a STAMFORD UNIVERSITY BANGLADESH   (Bangladesh)

^b BANGLADESH AGRICULTURAL UNIVERSITY   (Bangladesh)

^c KHULNA UNIVERSITY   (Bangladesh)

Author keywords

Arsenic; Atenolol; Bovine serum albumin; Drug interactions; Plasma protein binding

Indexed keywords

BOVINAE;

ARSENIC; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; SERUM ALBUMIN;

ANIMAL; ARTICLE; BINDING COMPETITION; BINDING SITE; BIOAVAILABILITY; CATTLE; CHEMISTRY; DRUG INTERACTION; HUMAN;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ARSENIC; ATENOLOL; BINDING SITES; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; CATTLE; DRUG INTERACTIONS; HUMANS; SERUM ALBUMIN;

EID: 63149160648     PISSN: 16060997     EISSN: None     Source Type: Journal    
DOI: 10.3329/jhpn.v27i1.3315     Document Type: Article

References (60)

1. Kober A, Sjöholm I. The binding sites on human serum albumin for some nonsteroidal antiinflammatory drugs. Mol Pharmacol 1980;18:421-6.
2. Kragh-Hansen U. Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 1981;33:17-53.
3. Peters T, Jr. All about albumin: biochemistry, genetics, and medical applications. San Diego, CA: Academic Press, 1996:1-132.
4. Fehske KJ, Müller WE, Wollert U. The location of drug binding sites in human serum albumin. Biochem Pharmacol 1981;30:687-92.
5. Sjöholm I, Ekman B , Kober A, Ljungstedt-Påhlman I, Seiving B, Sjödin T. Binding of drugs to human serum albumin: XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol Pharmacol 1979;16:767-77.
6. Kragh-Hansen U. Effect of aliphatic fatty acid on the binding of phenol red to human serum albumin. Biochem J 1981;195:603-13.
7. Nahar Z, Rhaman MH, Hasnat A. Interaction of nifedipine with BSA: effect of metals. Bangladesh J Physiol Pharmacol 1997;13:18-20.
8. Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975;11:824-32.
9. Sudlow G, Birkett DJ, Wade DN. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol 1976;12:1052-61.
10. Uddin SJ, Rouf R, Sen PK, Alam MA, Sarder MM, Alam SMM et al. In-vitro studies of the effect of arsenic on the binding of metronidazole at the binding sites of bovine serum albumin. Khulna Univ Stud 2005;6:73-6.
11. Uddin SJ, Shilpi JA, Murshid GMM, Rahman AA, Sarder MM, Alam MA. Determination of the binding sites of arsenic on bovine serum albumin using warfarin (site-I specific probe) and diazepam (site-II specific probe) J Biolog Sci 2004;4:609-12.
12. Alam MA, Awal MA, Mostofa M, Islam MK, Subhan N. In-vitro displacement interaction of atenolol and amlodipine on binding with bovine serum albumin when co-administered. Bangladesh J Pharmacol 2007;2:20-6.
13. Greminger P, Vetter H, Boerlin HJ, Baumgart P, Havelka J, Walger P et al. Atenolol, pindolol und propranolol bei essentieller hypertonie: ansprechquote und verträglichkeit. Schweiz Med Wochenschr 1982;112:1831-5.
14. Adamska-Dyniewska H. ß-adrenolytics-an update. Probl Ter Monit 1998;9:143-9.
15. Borchard U. Pharmacological properties of beta-adrenoceptor blocking drugs. J Clin Basic Cardiol 1998;1:5-9.
16. Telatyñska B, Wójcicki J, DroŸdzik M, Gawroñska-Szklarz B, Sulzyc-Bielicka V, Sterna R. Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. Pol J Pharmacol 2003;55:81-9.
17. Sassard J, Pozet N, McAinsh J, Legheand J, Zech P. Pharmacokinetics of atenolol in patients with renal impairment. Europ J Clinl Pharmacol 1977;12:175-80.
18. Sager G, Nilsen OG, Jacobsen S. Variable binding of propranolol in human serum. Biochem Pharmacol 1978;28: 905-11.
19. Wójcicki J, Kalinowski W, Gawroñska-Szklarz B. Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia. Arzneim-Forsch-Drug Res 1985;35: 911-93.
20. Lin JH, Cocchetto DM, Duggam DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflmmatory drugs. Clin Pharmacokinet 1987;12:402-32.
21. Seedher N, Agarwal P. Reversible binding of some isoxazolyl penicillins with serum albumin using fluorescence spectroscopic technique. Indian J Pharm Sci 2006;68:327-31.
22. Singlas E. Determination of protein binding and its characteristics: protein binding of drug. Chapter 1. 2nd ed. Basel: Hoffmann-La Roche, 1987:25-31.
23. Singlas E. Protein binding of drug. Chapter 1. 2nd ed. Basel: Hoffmann-La Roche, 1987:20-2.
24. Petitpas I, Bhattacharya AA, Twine S, East M, Curry S. Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J Biol Chem 2001;276:22804-9.
25. Belpaire FM, Bogaert MG, Rosseneu M. Binding of beta-adrenoceptor blocking drugs to human serum albumin, to alpha 1-acid glycoprotein and to human serum. Eur J Clin Pharmacol 1982;22:253-6.
26. Wellstein A, Palm D, Belz GG. Affinity and selectivi-ty of beta-adrenoceptorantagonists in vitro. J Cardiovasc Pharmacol 1986;8(Suppl II):S36-40.
27. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
28. Wallace A, Layug B, Tateo I, Li J, Hollenberg M, Browner W et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology 1998;88:7-17.
29. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Eng J Med 1996;335:1713-20.
30. George ST, Ruoho AE, Malbon CC. N-glycosylation in expression and function of beta-adrenergic receptors. J Biol Chem 1986;261:16559-64.
31. Herrmann V, Büscher R, Go MM, Ring KM, Hofer JK, Kailasam MT et al. Beta(2)-adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans. Am J Hypertens 2000;13:1021-6.
32. Devic E, Xiang Y, Gould D, Kobilka B. Beta-adrenergic receptor subtype-specific signaling in cardiac myocytes from beta(1) and beta(2) adrenoceptor knockout mice. Mol Pharmacol 2001;60:577-83.
33. Benovic JL, Onorato JJ, Arriza JL, Stone WC, LohseM, Jenkins NA et al. Cloning, expression, and chromosomal localization of beta-adrenergic receptor kinase 2. A new member of the receptor kinase family. J Biol Chem 1991;266:14939-46.
34. 2-adrenergic receptors in cultured keratinocytes. Archiv Dermatol Res 1998;290:402-4.
35. Chiang CE, Luk HN, Wang TM, Ding PY. Prolongation of cardiac repolarization by arsenic trioxide. Blood 2002;100:2249-52.
36. Tseng WP. Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 1977;19:109-19.
37. Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 1988;8:452-60.
38. Wu MM, Kuo TL, Hwang YH, Chen CJ. Dose-response relationship between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 1989;130:1123-32.
39. Chen CJ. Blackfoot disease. Lancet 1990;336:442.
40. Rosenberg HG. Systemic arterial disease and chronic arsenicism in infants. Arch Pathol 1974;97:360-5.
41. Zaldivar R. Arsenic contamination of drinking water and foodstuffs causing endemic chronic poisoning. Beitr Pathol 1974;151:384-400.
42. Borgono JM, Greiber R. Epidemiological study of arsenicism in the city of Antofagasta. In: Hemphill DD, editor. Trace substances in environmental health-VA symposium. Columbia, MO: University of Missouri Press, 1972:13-24.
43. Salcedo JC, Portales A, Landecho E, Diaz R. Transverse study of a group of patients with vasculopathy from chronic arsenic poisoning in communities of the Francisco de Madero and San Pedro Districts, Coahuila, Mexico. Rev Fac Medicina Torren 1984;12:16.
44. Rahman M, Tondel M, Ahmad SA, Chowdhury IA, Faruquee MH, Axelson O. Hypertension and arsenic exposure in Bangladesh. Hypertension 1999; 33:74-8.
45. Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM et al. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 1995;25:53-60.
46. Donofrio PD, Wilbourn AJ. Subacute arsenic toxicity presenting on clinical and electromyographic examination as Guillain-Barre syndrome. Ann Neurol 1985;18:156-7.
47. Hindmarsh JT, McCurdy RF. Clinical and environmental aspects of arsenic toxicity. Crit Rev Clin Lab Sci 1986;23:315-47.
48. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
49. Sardana MK, Drummond GS, Sassa S, Kappas A. The potent heme oxygenase inducing action of arsenic and parasiticidal arsenicals. Pharmacology 1981;23:247-53.
50. Albores A, Cebrian ME, Connelly JC, Bach PH, Bridges JW. Effect of arsenite on hepatic mixed-function oxidase activity in rats. Xenobiotica 1992;22:591-7.
51. Jacobs JM, Nichols CE, Andrew AS, Marek DE, Wood SG, Sinclair PR et al. Effect of arsenite on induction of CYP1A, CYP2B and CYP3A in primary cultures of rat hepatocytes. Toxicol Appl Pharmacol 1999;157:51-9.
52. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990;38:207-13.
53. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995;104:1-8.
54. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.
55. Vakharia DD, Liu N, Pause R, Fasco M, Bessette E, Zhang QY et al. Effect of metals on polycyclic aromatic hydrocarbon induction of CYP1A1 and CYP1A2 in human hepatocyte cultures. Toxicol Appl Pharmacol 2001;170:93-103.
56. Spink DC, Katz BH, Hussain MM, Spink BC, Wu SJ, Liu N et al. Induction of CYP1A1 and CYP1B1 in T-47D human breast cancer cells by benzo[a]pyrene is diminished by arsenite. Drug Metab Dispos 2002;30:262-9.
57. Bessette EE, Fasco MJ, Pentecost BT, Kaminsky LS. Mechanisms of arsenite-mediated decreases in benzo(k)fluoranthene-induced human cytochrome P4501A1 levels in HepG2 cells. Drug Metab Dispos 2005; 33:312-20.
58. Vernhet L, Allain N, Lee Vée M, Morel F, Guillouzo A, Fardel O. Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons. J Pharmacol Exp Ther 2003;304:145-55.
59. Gerhardt RE, Hudson JB, Rao RN, Sobel RE. Chronic renal insufficiency from cortical necrosis induced by arsenic poisoning. Arch Intern Med 1978;138:1267-9.
60. Hamamoto E. Infant arsenic poisoning by powdered milk. Nihon Lji Shinpo 1955;1649:3-12 (Japanese).